Prostate Cancer Prospective Cohort

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00937586

Enrollment

1937

Registered

2009-07-13

Start date

2000-05-31

Completion date

2027-06-30

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

Metastatic Prostate Cancer, Prostate Cancer Risk Assessment

Brief summary

The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.

Detailed description

DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively. A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to 100 Years

Healthy volunteers

Yes

Inclusion criteria

* Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy.

Exclusion criteria

* Newly diagnosed patients: 1. inability to give informed consent

Design outcomes

Primary

Measure	Time frame
Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms.	At the time of prostate cancer diagnosis

Secondary

Measure	Time frame
Ability to predict risk for treatment failure based on analysis of specific polymorphisms.	At the time of prostate cancer diagnosis

Countries

United States

Outcome results